Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Hematology|November 19, 2010
Potential of mTOR inhibitors as therapeutic agents in hematological malignanciesKamalesh Sankhala, Francis J Giles
Targeted Oncology|May 3, 2011
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomasSushma Vemulapalli, Alain Mita, Yesid Alvarado, et al.
Expert Opinion on Investigational Drugs|November 18, 2008
Deforolimus (AP23573) a novel mTOR inhibitor in clinical developmentMonica Mita, Kamalesh Sankhala, Issam Abdel-Karim, et al.
Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.
Future Oncology (London, England)|April 21, 2009
Targeting the mTOR pathway using deforolimus in cancer therapyDevalingam Mahalingam, Kamalesh Sankhala, Alain Mita, et al.
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
Investigational New Drugs|April 19, 2018
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedulesKamalesh Sankhala, Chris H Takimoto, Alain C Mita, et al.
Molecular Cancer Therapeutics|December 29, 2011
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumorsRazelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, et al.
JAMA Oncology|September 18, 2015
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical TrialSant P Chawla, Zsuzsanna Papai, Guzel Mukhametshina, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaDevalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, et al.
Pageof 2